Novo Nordisk Shows It Is Ready To Extend Its Obesity Portfolio

Novel Oral Obesity Drug Shows Promise

 
• By Jessica Merrill

During a capital markets day, the company highlighted Phase I weight loss data for its novel oral obesity drug amycretin, which could work in a complementary fashion to GLP-1s. 

scale
Novo Nordisk revealed new obesity drug data • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas